Eosinophilic Esophagitis in the Spotlight

Program Description

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease with an evolving therapeutic landscape. This Science in the Spotlight™ symposium begins with a dynamic whiteboard animation that engages learners and shifts clinical thinking from symptom-based management toward a mechanism-driven approach to patient assessment and treatment. Faculty will explore the role of epithelial signaling and upstream alarmin cytokines in EoE pathogenesis before examining emerging biologic therapies targeting these pathways. Through interactive polling, practical clinical application, and expert discussion, attendees will gain evidence-based strategies to improve the diagnosis, evaluation, therapeutic selection, and long-term management of patients with EoE.

Target Audience

This educational activity has been designed to educate gastroenterology and allergy/clinical immunology clinicians who manage patients with eosinophilic esophagitis (EoE).

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

1. Discuss the contributions of epithelial cytokine signaling to the pathophysiology of EoE, including implications for progression risks and treatment options
2. Evaluate patients with suspected EoE in accordance with recent evidence-based guidelines
3. Describe the clinical rational and published trial evidence for emerging biologic therapies in the treatment of EoE, including anti-TSLP agents

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must take the pretest, view the content, pass the posttest with a 70% or higher, and complete the evaluation.

Disclosures of Conflicts of Interest 

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies: 

Maureen Bauer, MD: 

• Consulting Fees (e.g., advisory boards): DBV, DynaMed, Sanofi/Regeneron 

Evan S. Dellon, MD, MPH:

• Consulting Fees (e.g., advisory boards): AbbVie, Adare/Ellodi, Alfasigma, ALK, Allakos, Amgen, AnaptysBio, Apogee, Apollo, Aqilion, Arena/Pfizer, AstraZeneca, Bethanamist, BioCryst, Bryn, Calypso, Celgene/Receptos/BMS, Celldex, Cyted, Domain, Eli Lilly, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GI Reviewers, GSK, Holoclara, Invea, Knightpoint, Kymera, LucidDx, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Roivant, Sanofi, Shire/Takeda, Target RWE, Third Harmonic Bio, Upstream Bio 
• Contracted Research: Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celldex, Celgene/Receptos/BMS, Dr. Falk Pharma, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Phathom, Regeneron, Revolo, Sanofi, Shire/Takeda, Uniquity 
• Other (Educational Grants): Allakos, Aqilion, Holoclara, Invea 

Girish Hiremath, MD, MPH:

• Consulting Fees (e.g., advisory boards): Amgen, AstraZeneca, Eupraxia, Kaplan Inc., Sanofi, Regeneron, Takeda 

The Integritas planners and managers have no relevant financial relationships to disclose. 

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Fee Information & Refund/Cancellation Policy

There is no fee for this activity.

Integritas Contact Information

For information about this program, please contact us at info@exchangecme.com.